76 related articles for article (PubMed ID: 20661695)
21. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
Orki A; Akin O; Tasci AE; Ciftci H; Urek S; Falay O; Kutlu CA
Thorac Cardiovasc Surg; 2009 Jun; 57(4):217-21. PubMed ID: 19670115
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin levels in an asbestos-exposed population.
Park EK; Thomas PS; Johnson AR; Yates DH
Clin Cancer Res; 2009 Feb; 15(4):1362-6. PubMed ID: 19174489
[TBL] [Abstract][Full Text] [Related]
23. Current state and future directions of pleural mesothelioma imaging.
Armato SG; Entwisle J; Truong MT; Nowak AK; Ceresoli GL; Zhao B; Misri R; Kindler HL
Lung Cancer; 2008 Mar; 59(3):411-20. PubMed ID: 18061303
[TBL] [Abstract][Full Text] [Related]
24. Morphologic and functional imaging of malignant pleural mesothelioma.
Yamamuro M; Gerbaudo VH; Gill RR; Jacobson FL; Sugarbaker DJ; Hatabu H
Eur J Radiol; 2007 Dec; 64(3):356-66. PubMed ID: 17954021
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for mesothelioma.
Scherpereel A; Lee YC
Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
[TBL] [Abstract][Full Text] [Related]
26. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET and PET/CT in fever of unknown origin.
Meller J; Sahlmann CO; Scheel AK
J Nucl Med; 2007 Jan; 48(1):35-45. PubMed ID: 17204697
[TBL] [Abstract][Full Text] [Related]
28. Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.
Okten F; Köksal D; Onal M; Ozcan A; Simşek C; Ertürk H
Clin Imaging; 2006; 30(3):177-80. PubMed ID: 16632152
[TBL] [Abstract][Full Text] [Related]
29. Advances in malignant mesothelioma.
Robinson BW; Lake RA
N Engl J Med; 2005 Oct; 353(15):1591-603. PubMed ID: 16221782
[No Abstract] [Full Text] [Related]
30. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
31. The role of PET in the surgical management of malignant pleural mesothelioma.
Flores RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S27-32. PubMed ID: 15950796
[TBL] [Abstract][Full Text] [Related]
32. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
Erasmus JJ; Truong MT; Smythe WR; Munden RF; Marom EM; Rice DC; Vaporciyan AA; Walsh GL; Sabloff BS; Broemeling LD; Stevens CW; Pisters KM; Podoloff DA; Macapinlac HA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1364-70. PubMed ID: 15942579
[TBL] [Abstract][Full Text] [Related]
33. Role of osteopontin in adhesion, migration, cell survival and bone remodeling.
Standal T; Borset M; Sundan A
Exp Oncol; 2004 Sep; 26(3):179-84. PubMed ID: 15494684
[TBL] [Abstract][Full Text] [Related]
34. PET for the evaluation of pleural thickening observed on CT.
Kramer H; Pieterman RM; Slebos DJ; Timens W; Vaalburg W; Koëter GH; Groen HJ
J Nucl Med; 2004 Jun; 45(6):995-8. PubMed ID: 15181135
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
Duysinx B; Nguyen D; Louis R; Cataldo D; Belhocine T; Bartsch P; Bury T
Chest; 2004 Feb; 125(2):489-93. PubMed ID: 14769729
[TBL] [Abstract][Full Text] [Related]
36. The role of osteopontin in lung disease.
O'Regan A
Cytokine Growth Factor Rev; 2003 Dec; 14(6):479-88. PubMed ID: 14563350
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2003 Jul; 126(1):11-6. PubMed ID: 12878934
[TBL] [Abstract][Full Text] [Related]
38. Survival after pleural malignant mesothelioma: a population-based study in Italy.
Magnani C; Viscomi S; Dalmasso P; Ivaldi C; Mirabelli D; Terracini B
Tumori; 2002; 88(4):266-9. PubMed ID: 12400973
[TBL] [Abstract][Full Text] [Related]
39. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
Gerbaudo VH; Sugarbaker DJ; Britz-Cunningham S; Di Carli MF; Mauceri C; Treves ST
J Nucl Med; 2002 Sep; 43(9):1144-9. PubMed ID: 12215551
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin as a potential diagnostic biomarker for ovarian cancer.
Kim JH; Skates SJ; Uede T; Wong KK; Schorge JO; Feltmate CM; Berkowitz RS; Cramer DW; Mok SC
JAMA; 2002 Apr; 287(13):1671-9. PubMed ID: 11926891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
